Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Although hepatocellular carcinoma (HCC) is one of the deadliest health burdens worldwide,
few drugs are available for its clinical treatment. However, in recent years, major …

Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma
(HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the …

Hepatitis B virus (HBV) contributes to hepatocellular carcinoma (HCC) development through
direct and indirect mechanisms. HBV DNA integration into the host genome occurs at early …

Hepatocellular carcinoma (HCC) is the most frequent liver cancer with high lethality and low
five-year survival rates leading to a substantial worldwide burden for healthcare systems …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related mortality.
The principal treatment is surgical resection or liver transplantation, depending on whether …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

BACKGROUND & AIMS: Tremelimumab is a monoclonal antibody that blocks cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4), an inhibitory co-receptor that interferes with T …

Nanoparticles have emerged as promising drug delivery systems for the treatment of several
diseases. Novel cancer therapies have exploited these particles as alternative adjuvant …